A carregar...
Tyrosine kinase inhibitor associated vascular toxicity in chronic myeloid leukemia
Tyrosine kinase inhibitors (TKIs) have revolutionized the management and outcomes of chronic myeloid leukemia (CML) patients. Improved disease control and prolonged life expectancy now mandate focus on improving TKIs’ safety profile. Recently, vascular adverse events (VAEs) have emerged as a serious...
Na minha lista:
| Publicado no: | Cardiooncology |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
BioMed Central
2015
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7837152/ https://ncbi.nlm.nih.gov/pubmed/33530148 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40959-015-0008-5 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|